Biology:Sitagliptin
![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /sɪtəˈɡlɪptɪn/ (![]() |
Trade names | Januvia, Zituvio, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606023 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 87% |
Protein binding | 38% |
Metabolism | Liver (CYP3A4- and CYP2C8-mediated) |
Elimination half-life | 8 to 14 h[5] |
Excretion | Kidney (80%)[5] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H15F6N5O |
Molar mass | 407.320 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes.[6] In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea.[7] It is taken by mouth.[6] It is also available in the fixed-dose combination medication sitagliptin/metformin (Janumet, Janumet XR).[6]
Common side effects include headaches, swelling of the legs, and upper respiratory tract infections.[6] Serious side effects may include angioedema, low blood sugar, kidney problems, pancreatitis, and joint pain.[6] Whether use in pregnancy or breastfeeding is safe is unclear.[8] It is in the dipeptidyl peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.[6]
Sitagliptin was developed by Merck & Co. and approved for medical use in the United States in 2006.[6] In 2020, it was the 74th most commonly prescribed medication in the United States, with more than 9 million prescriptions.[9][10] As of 2023, it is available as a generic medication in Canada but not the United States.[11][12]
Medical uses
Sitagliptin is used to treat type 2 diabetes.[6] It is generally less preferred than metformin or sulfonylureas.[7] It is taken by mouth.[6] It is also available as the fixed-dose combinations of sitagliptin/metformin (Janumet, Janumet XR)[6] and sitagliptin/simvastatin (Juvisync).[13]
Sitagliptin should not be used to treat type 1 diabetes. In December 2020, the U.S. Food and Drug Administration (FDA) approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in children aged 10 to 17 with type 2 diabetes.[14] The drugs are approved to improve blood sugar control in adults aged 18 and older with type 2 diabetes.[14]
Adverse effects
Adverse effects from sitagliptin are similar to placebo, except for rare nausea, common cold-like symptoms, and photosensitivity.[15] It does not increase the risk of diarrhea.[16] No significant difference exists in the occurrence of hypoglycemia between placebo and sitagliptin.[15][17][18] In those taking sulphonylureas, the risk of low blood sugar is increased.[19]
The existence of rare case reports of kidney failure and hypersensitivity reactions is noted in the United States prescribing information, but a causative role for sitagliptin has not been established.[1]
Several postmarketing reports of pancreatitis (some fatal) have been made in people treated with sitagliptin and other DPP-4 inhibitors,[20][21] and the U.S. package insert carries a warning to this effect,[1] although the causal link between sitagliptin and pancreatitis has not yet been fully substantiated.[22] One study with lab rats published in 2009 concluded that some of the possible risks of pancreatitis or pancreatic cancer may be reduced when it is used with metformin. However, while DPP-4 inhibitors showed an increase in such risk factors, as of 2009, no increase in pancreatic cancer has been reported in individuals taking DPP-4 inhibitors.[23]
In 2015, the U.S. Food and Drug Administration (FDA) added a new warning and precaution about the risk of "severe and disabling" joint pain to the labels of all DPP-4 inhibitor medicines.[24]
Mechanism of action
Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones released in response to a meal.[25] By preventing breakdown of GLP-1 and GIP, they are able to increase the secretion of insulin and suppress the release of glucagon by the alpha cells of the pancreas. This drives blood glucose levels towards normal. As the blood glucose level approaches normal, the amounts of insulin released and glucagon suppressed diminishes, thus tending to prevent an "overshoot" and subsequent low blood sugar (hypoglycemia), which is seen with some other oral hypoglycemic agents.
Sitagliptin has been shown to lower HbA1c level by about 0.7% points versus placebo. It is slightly less effective than metformin when used as a monotherapy. It does not cause weight gain and has less hypoglycemia compared to sulfonylureas. Sitagliptin is recommended as a second-line drug (in combination with other drugs) after the combination of diet/exercise and metformin fails.[26]
History
Sitagliptin was approved by the U.S. Food and Drug Administration (FDA) in October 2006,[27] and is marketed in the US as Januvia by Merck & Co. On April 2, 2007, the FDA approved an oral combination of sitagliptin/metformin sold in the US under the brand name Janumet. On October 7, 2011, the FDA approved an oral combination of sitagliptin/simvastatin marketed in the US as Juvisync.[13]
References
- ↑ 1.0 1.1 1.2 "Januvia- sitagliptin tablet, film coated". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f85a48d0-0407-4c50-b0fa-7673a160bf01.
- ↑ "Zituvio- sitagliptin tablet". 1 November 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2da9d77-154b-48f7-8793-3f4a24dfafc6.
- ↑ "Zituvio- sitagliptin tablet". 1 November 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abfdea45-c0ca-41e3-a510-e89810bc9cfe.
- ↑ "Januvia EPAR". September 17, 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/januvia.
- ↑ 5.0 5.1 "Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses". Clinical Pharmacology and Therapeutics 78 (6): 675–688. December 2005. doi:10.1016/j.clpt.2005.09.002. PMID 16338283.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 "Sitagliptin Monograph for Professionals". American Society of Health-System Pharmacists. https://www.drugs.com/monograph/sitagliptin.html.
- ↑ 7.0 7.1 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 681. ISBN 9780857113382.
- ↑ "Sitagliptin Pregnancy and Breastfeeding Warnings". https://www.drugs.com/pregnancy/sitagliptin.html.
- ↑ "The Top 300 of 2020". https://clincalc.com/DrugStats/Top300Drugs.aspx.
- ↑ "Sitagliptin - Drug Usage Statistics". https://clincalc.com/DrugStats/Drugs/Sitagliptin.
- ↑ "Generic Januvia Availability" (in en). Drugs.com. https://www.drugs.com/availability/generic-januvia.html.
- ↑ "JAMP Pharma Group receives Health Canada approval for PrJAMP Sitagliptin, a new generic alternative for the treatment of type 2 diabetes" (Press release). JAMP Pharma. 6 January 2023. Retrieved 19 June 2023 – via Newswire.
- ↑ 13.0 13.1 "FDA Approves Combination Therapy Juvisync" (Press release). U.S. Food and Drug Administration. October 7, 2011. Archived from the original on August 24, 2014. Retrieved November 17, 2013.
- ↑ 14.0 14.1 "Diabetes drug not proven to improve blood sugar in pediatric patients". December 4, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/new-studies-show-diabetes-drug-not-proven-improve-blood-sugar-control-pediatric-patients.
This article incorporates text from this source, which is in the public domain.
- ↑ 15.0 15.1 "Januvia Side Effects & Drug Interactions". RxList.com. 2007. http://www.rxlist.com/cgi/generic/januvia_ad.htm.
- ↑ "Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials". Drug Design, Development and Therapy 8: 2283–2294. 2014. doi:10.2147/DDDT.S70945. PMID 25419118.
- ↑ "Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®)". Dermatology Online Journal 18 (2): 9. February 2012. doi:10.5070/D30D70K7B2. PMID 22398230. https://escholarship.org/uc/item/0d70k7b2. Retrieved June 6, 2019.
- ↑ "Januvia side effect: Photosensitivity reaction - eHealthMe". https://www.ehealthme.com/ds/januvia/photosensitivity-reaction/.
- ↑ "Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis". BMJ 353: i2231. May 2016. doi:10.1136/bmj.i2231. PMID 27142267.
- ↑ "Do incretin-based therapies cause acute pancreatitis?". Journal of Diabetes Science and Technology 4 (1): 228–229. January 2010. doi:10.1177/193229681000400129. PMID 20167189.
- ↑ "FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes". 21 June 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre.
- ↑ National Prescribing Service (August 2010). "Sitagliptin for Type 2 Diabetes". http://www.nps.org.au/consumers/publications/medicine_update/issues/sitagliptin.
- ↑ "Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin". Diabetes 58 (7): 1604–1615. July 2009. doi:10.2337/db09-0058. PMID 19403868.
- ↑ "DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication—May Cause Severe Joint Pain". August 28, 2015. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain.
- ↑ "Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects". Journal of Clinical Pharmacology 46 (8): 876–886. August 2006. doi:10.1177/0091270006289850. PMID 16855072.
- ↑ "Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes". Clinical Medicine: Therapeutics 1 (1): 53–62. 2009. doi:10.4137/CMT.S2313.
- ↑ "FDA Approves New Treatment for Diabetes" (Press release). U.S. Food and Drug Administration (FDA). October 17, 2006. Archived from the original on February 28, 2009. Retrieved October 17, 2006.
External links
- "Sitagliptin". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/sitagliptin.
- "Sitagliptin phosphate". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/rn/654671-77-9.
![]() | Original source: https://en.wikipedia.org/wiki/Sitagliptin.
Read more |